DVAX: dynavax.com Company Value to Net Income

Symbol and logo of brand Dynavax Pharma (DVAX)

Dynavax Technologies (DVAX) supplies proven hepatitis vaccines, ensuring stable sales through its patents. However, geopolitical conflicts could disrupt raw material supplies and complicate international certification. Revenues are based on hepatitis B drugs and the success of new R&D developments. The company's weighted average P/E reflects the dynamics of return on capital, where the value -41.50 describes the current level of market valuation.

DVAX - Dynavax Technologies Corp P/E Multiple over the range 07/04/2022 - 02/21/2026

Comprehensive metric breakdowns and analytics for Dynavax Technologies (DVAX)

- price and consensus price forecast:
Stock Price Dynavax Corp|DVAX - Consensus Target
- market capitalization information:
Market Value Dynavax Technologies Corporation|DVAX - Total Company Value
- balance sheet net asset value indicators:
Net Assets per Single Share Dynavax|DVAX - Book Capitalization|Market Capitalization to Book Value dynavax.com|DVAX - Cumulative Company Assets
- company liabilities and liquidity data:
Debt to Equity Dynavax Technologies|DVAX - Long-Term Debt to Capital|Current Liabilities to Capital dynavax.com|DVAX - Company Debts|Debt to Net Assets Ratio Dynavax Technologies Corporation|DVAX - Company Long-Term Debts|Company Short-Term Indebtedness Dynavax|Immediate Liquidity dynavax.com
- earnings and market ratios statistics:
DVAX - Company Net Income|Net Profit Forecast Dynavax Technologies|DVAX - P/E Multiple|Forward P/E Multiple Dynavax Technologies Corp|DVAX - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Dynavax Technologies Corporation|DVAX - Operating profit EBITDA|Net earnings per share (EPS TTM) Dynavax|DVAX - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last 12 months dynavax.com|DVAX - Net earnings per share growth this year|Expected earnings per share trend next year Dynavax Technologies
- company sales and revenue statistics:
DVAX - Company Sales|Company Projected Revenue Volume Dynavax Technologies|DVAX - P/S Multiple|Market Cap to Future Revenue Ratio Dynavax Technologies Corporation
Comprehensive company analysis:Dynavax Technologies Corporation - DVAX
Brand item of Dynavax Technologies Corp

The P/E ratio compares the current market value of a business to its net income, determining the actual cost of each dollar of earnings. By analyzing the P/E history of Dynavax Technologies (DVAX), an investor can identify asset overvaluation or hidden risks, which is critical for Dynavax Technologies (DVAX) due to its reliance on a single drug and the need for large-scale R&D investments to diversify its portfolio.

Key competitors

P/E Multiple arrowheadpharma.com|Price to Earnings Ratio MIRM (Mirum)|ABUS (Arbutus Biopharma Corp) - Company Value to Net Income|Price to Earnings Ratio Inventiva Pharma IVA|Gyre Therapeutics Corp. - Price to Earnings Ratio|Assembly Biosciences - P/E Multiple|Business Payback Period Galectin Therapeutics GALT|GNFT (genfit.com) - Price to Earnings Ratio|DRRX (DURECT) - Price to Earnings Ratio|ALGS (Aligos Therapeutics Inc.) - P/E Multiple|Market Cap to Earnings BioVie Pharma BIVI|Price to Earnings Ratio Galmed Pharmaceuticals (GLMD)|NDRA (endrainc.com) - Company Value to Net Income|P/E Multiple HEPA (Hepion Pharmaceuticals, Inc.)